SOPHiA GENETICS was founded in 2011 by biologists who had a vision to create a technology that could make a positive and lasting impact on the world, using data for good. We’ve built a revolutionary technology platform, SOPHiA DDM™, that rapidly distills complex data into actionable insights, enabling clinicians, researchers, and biopharma to reshape the way that we diagnose and treat cancer and rare inherited disorders. The AI fueling our platform learns from the complex genomic and multimodal data provided by our community of users to create a collective intelligence over time. By using the power of data and AI, we are expanding access to data-driven medicine and enabling the patients of today to help the patients of tomorrow. Our science is driven by unrelenting passion for our mission to transform patient care by expanding access to data-driven medicine globally. We wouldn’t be able to achieve all that we have – and all that we will – without our people, who are driven by our shared purpose to ensure that every patient worldwide has equitable access to precision medicine. Our virtues are our behaviors we exhibit every day, and our mantra “We Care” is our driving force.
Unlock the market timeline & signal feed
2,182 signals in the last 90 days.
The order this company entered each market — oldest to newest
Como o Hospital Mário Penna incorporou NGS à rotina para diagnóstico de neoplasias hematológicas?Implementar uma nova tecnologia em laboratório clínico vai muito além da parte técnica — envolve confiança, adaptação e aprendizado contínuo.Neste webinar, a equipe do Hospital Mário Penna abre as portas do seu laboratório para contar como incorporou duas aplicações de NGS à rotina para investigação de neoplasias mieloides e linfoídes, desde a avaliação do desempenho analítico até os primeiros casos ...
A experiência do Hospital Mário Penna na implementação de soluções para investigação de doenças onco-hematológicas
Sign up to see the full signal feed
How SOPHiA GENETICS's international expansion compares to its competitors
SOPHiA GENETICSYouBars show relative size across the companies compared.
5 metrics| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 SOPHiA GENETICSYou | 11 | 0 | -54% | 2.2k | 21 |
Scaling fast — 46 roles opened in the last 90 days, up 183% vs the prior period. Sales-led and concentrated in Switzerland.
Boston, MA · 2d ago
Senior Software Engineer
Singapore · 5d ago
Director, Subject Matter Expert - APAC
Colombia · last wk.
Associate Director / Sr Manager, BioPharma Business Development (West / Central)
49 technologies detected across the stack.
32 active campaigns across 226 markets.
Ended
Ended
Ended3 mentions in the last 90 days.
SOPHiA GENETICS SA published a slide deck in conjunction with their Q2 2026 earnings call, with transcript coverage provided by Seeking Alpha.
SOPHiA Genetics reported Q2 2026 results with revenue of $23.3M, up 27.2% YoY, beating estimates. GAAP EPS of -$0.30 missed by $0.08. Gross margin declined to 64.6% reported and 72.1% adjusted.
SOPHiA GENETICS announced a multi-year collaboration with AstraZeneca to develop and deploy two companion diagnostics for precision oncology therapies, advancing decentralized clinical trial assays globally.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about SOPHiA GENETICS's business, markets, and growth signals.
“We reach accounts the week they land in-market — not the quarter after.”
Book a walkthrough of the movement map with our team.
Pubrio turns expansion signals across 200+ markets into one live graph, so revenue teams see which companies are entering new markets, and act on the timing.
© 2026 Pubrio. All rights reserved.
